Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mibampator. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 known ✓ | P48058 | 17/20 | 1.00 |
| ▸ | GRIA2 known ✓ | P42262 | 3/20 | 0.59 |
| ▸ | GRIA1 known ✓ | P42261 | 1/20 | 0.59 |
| ▸ | GRIA3 known ✓ | P42263 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mibampator SCHEMBL3045499 | 1.00 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3POLB | |
| Mibampator SCHEMBL3074747 | 1.00 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3POLB | |
| SCHEMBL6563305 | 0.96 | GRIA4 (0.92) | GRIA4GRIA2GRIA1GRIA3POLB | |
| SCHEMBL5877913 | 0.93 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6563303 | 0.89 | GRIA4 (0.80) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878077 | 0.88 | GRIA4 (0.79) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6565213 | 0.88 | GRIA4 (0.79) | GRIA4GRIA2GRIA1GRIA3POLB | |
| SCHEMBL719605 | 0.86 | GRIA4 (0.76) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL719606 | 0.86 | GRIA4 (0.76) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878035 | 0.85 | GRIA4 (0.74) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | disclosed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003032974-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | GRIA4 212/4885GRIA2 176/4885GRIA1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.